The present invention provides a method for quantifying modified HDL contained in a sample, comprising binding a modified HDL to a modified HDL-binding protein, and quantifying a complex of the modified HDL-binding protein and the modified HDL, wherein the modified HDL-binding protein comprises a protein having a sequence of an L chain region of Factor V, or a variant thereof.

This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.

This invention provides minimally invasive methods, reagents, diagnostic and prognostic markers useful for staging, prognosis and surveillance of colorectal cancers, and therapeutic intervention in individuals with colorectal cancers, or individuals who may be susceptible to developing colorectal cancers.

Certain aspects of the disclosure provide systems and methods for diagnosing and treating chronic liver disease and portal vein thrombosis. In particular, methods may include measuring levels of one or more proteins, including factor V, factor VIII, protein C, protein S, D-dimer, sP-selectin, or asTF in a biological sample from a subject and determining a CLD score based on the levels of the one or more proteins, whereby, a CLD stage may be determined based on the CLD score. In some aspects, methods may include determining a PVT score based on levels of the one or more proteins in the biological sample. In some aspects, methods further include treating CLD and/or PVT.